Damora Therapeutics Inc.

06/17/2026 | Press release | Distributed by Public on 06/17/2026 14:00

Proxy Results (Form 8-K)

Item 5.07

Submission of Matters to a Vote of Security Holders.

Damora Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders on June 17, 2026 (the "Annual Meeting"). The following proposals were submitted to the stockholders of the Company at the Annual Meeting, which are described in detail in the the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026 (the "Proxy Statement"):

1.
To elect Michael Landsittel and Cameron Turtle, D.Phil, as Class III members of the Board of Directors (the "Board"), to serve until the Company's 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal (the "Election of Directors Proposal");
2.
To approve, on an advisory basis, the compensation paid to the Company's named executive officers (the "Say-on-Pay Proposal");
3.
To conduct an advisory vote on the frequency of future advisory votes to approve the compensation paid to the Company's named executive officers (the "Say-on-Frequency Proposal"); and
4.
To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 (the "Ratification of Auditor Proposal").

There were 60,303,212 shares of Common Stock outstanding and entitled to vote on April 22, 2026, the record date for the Annual Meeting, and 55,009,938 shares of Common Stock were represented in person or by proxy at the Annual Meeting, which number constituted a quorum.

At the Annual Meeting, each of the Company's director nominees was elected, a frequency of one year received the plurality of votes cast on the Say-on-Frequency Proposal and the other proposals voted on were approved. The final voting results regarding each proposal are set forth below.

1.
Election of Directors Proposal.

Nominees

For

Withheld

Broker Non-Votes

Michael Landsittel

51,403,541

29,011

3,577,386

Cameron Turtle, D.Phil

51,403,540

29,012

3,577,386

2.
Say-on-Pay Proposal.

For

Against

Abstain

Broker Non-Votes

51,401,988

3,546

27,018

3,577,386

3.
Say-on-Frequency Proposal.

1 Year

2 Years

3 Years

Abstain

50,913,167

103

518,015

1,267

In light of these voting results and in accordance with its prior recommendation, the Board has determined that the Company will hold future Say-on-Pay votes every year until the next required Say-on-Frequency vote.

4.
Ratification of Auditor Proposal.

For

Against

Abstain

Broker Non-Votes

54,977,317

5,640

26,981

-

Damora Therapeutics Inc. published this content on June 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 17, 2026 at 20:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]